Troponins are regulatory proteins that form the cornerstone of muscle contraction. The amino acid sequences of cardiac troponins differentiate them from that of skeletal muscles, allowing for the development of monoclonal antibody-based assay of troponin I (TnI) and troponin T (TnT). Along with the patient history, physical examination and electrocardiography, the measurement of highly sensitive and specific cardiac troponin has supplanted the former gold standard biomarker (creatine kinase-MB) to detect myocardial damage and estimate the prognosis of patients with ischemic heart disease. The current guidelines for the diagnosis of non-ST segment elevation myocardial infarction are largely based on an elevated troponin level. The implementation of these new guidelines in clinical practice has led to a substantial increase in the frequency of myocardial infarction diagnosis. Automated assays using cardiac-specific monoclonal antibodies to cardiac TnI and TnT are commercially available. They play a major role in the evaluation of myocardial injury and prediction of cardiovascular outcome in cardiac and non-cardiac causes. In this review we discuss the clinical applications of cardiac troponins and the interpretation of elevated levels in the context of various clinical settings.
Despite the fact that CABG is the standard of care for patients with multivessel coronary arteries and/or left main stem stenosis, PCI has become a rival to CABG in patients with multivessel coronary artery disease or left main disease. However, the need for repeat revascularization, in-stent stenosis and thrombosis remain the achilis heal of PCI. SYNTAX trial randomized patients with left main disease and/or three-vessel disease to PCI with TAXus stent or CABG with the concept that PCI is not inferior to CABG. At 1 and 2 years follow up, MACCE was significantly increased in PCI patients mainly attributed to increased rate of repeat revascularization; however, stroke was significantly more with CABG. The composite safety endpoint of death/stroke/MI was comparable between the 2 groups. Therefore the criterion for non-inferiority was not met. What we learn from SYNTAX is that multi disciplinary team approach should be the standard of care when recommending treatment in more complex coronary artery disease. SYNTAX makes interventionists and surgeons come together, it may set the benchmark for MVD revascularization. PCI and CABG should be considered complementary rather than competitive revascularization strategies. There is no substitute for sound clinical judgment that takes into account the patient's overall clinical profile, functionality, co-morbidities, as well as the patient's coronary anatomy. The SYNTAX Score should be utilized to decide on treatment of patients with LM/MVD. Patients with low and intermediate score can be treated with PCI or CABG with equal results. Those with high score do better with CABG. SYNTAX trial showed that 66% of patients with 3VD or LMD are still best treated with CABG. In the remaining 1/3 of patients with low syntax score, PCI may be considered as an alternative to surgery. Finally, medical treatment should be optimized in patients going for CABG.
Introduction: Evaluate the effects of baseline anemia and anemia following revascularization on outcomes in patients with Unprotected Left Main Coronary Artery (ULMCA) disease. Methods: This was a retrospective, multicenter, observational study conducted between January 2015 to December 2019. The data on patients with ULMCA who underwent revascularization through PCI or CABG was stratified by hemoglobin level at baseline into anemic and non-anemic groups to compare in-hospital events. The pre-discharge hemoglobin following revascularization was categorized into very low (<80 g/L for men & women), low (≥80 & ≤119 g/L for women & ≤129 g/L for men) and normal (≥130 g/L for men & ≥120 g/L for women) to assess impact on follow-up outcomes. Results: A total of 2138 patients were included, 796 (37.2%) of which had anemia at baseline. A total of 319 developed anemia after revascularization and moved from being non-anemic at baseline to anemic at discharge. There was no difference in hospital MACE and mortality between CABG and PCI in anemic patients. At a median follow-up time of 20 months (IQR: 27), patients with pre-discharge anemia who underwent PCI had higher incidence of congestive heart failure (P< 0.0001), and those who underwent CABG had significantly higher follow-up mortality (HR: 9.85 (95% CI: 2.53- 38.43), P= 0.001). Discussion/Conclusion: In this Gulf LM study, baseline anemia had no impact upon in-hospital MACCE and total mortality following revascularization (PCI or CABG). However, pre-discharge anemia is associated with worse outcomes after unprotected LMCA disease revascularization, with significantly higher all-cause mortality in patients who had CABG, and higher incidence of CHF in PCI patients, at a median follow-up time of 20 months (IQR: 27).
Introduction Bleeding after transcatheter aortic valve replacement (TAVR) has a negative impact on the outcome of the procedure. Risk factors for bleeding vary widely in the literature, and the impact of preoperative antithrombotic agents has not been fully established. The objectives of our study were to assess bleeding after TAVR as defined by the Valve Academic Research Consortium-2 (VARC-2), identify its risk factors, and correlate with antithrombotic treatment in addition to its effect on procedural mortality. Methods The study included 374 patients who underwent TAVR from 2009 to 2018. We grouped the patients into four groups according to the VARC-2 definition of bleeding. Group 1 included patients without bleeding (n=265), group 2 with minor bleeding (n=22), group 3 with major bleeding (n=61), and group 4 with life-threatening bleeding (n=26). The median age was 78 (25 th -75 th percentiles: 71-82), and 226 (60.4%) were male. The median EuroSCORE was 3.4 (2-6.3), and there was no difference among groups ( P =0.886). The TAVR approach was transfemoral (90.9%), transapical (5.6%), and trans-subclavian (1.9%). Results: Predictors of bleeding were stroke (OR: 2.465; P =0.024) and kidney failure (OR: 2.060; P =0.046). Preoperative single and dual antiplatelet therapy did not increase the risk of bleeding ( P =0.163 and 0.1, respectively). Thirty-day mortality occurred in 14 patients (3.7%), and was significantly higher in patients with life-threatening bleeding (n=8 [30.8%]; P <0.001). Conclusion: Bleeding after TAVR is common and can be predicted based on preprocedural comorbidities. Preprocedural antithrombotic therapy did not affect bleeding after TAVR in our population.
Funding Acknowledgements This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors Background Radial artery spasm (RAS) is one of the most common complication encountered by operators while performing trans-radial artery cardiac catheterization. Due to the technological advances in recent years and the increase number of experts in high volume centers, the prophylactic use of vasodilators may be unnecessary. To date, there are no clear recommendations for using these vasodilators and when to be used in day to day practice. Basically, It depends on operators discretion and hospital protocol. Therefore, further research in this area is warranted due to the conflicting findings of the prior studies. purpose To evaluate the need of using prophylactic vasodilators prior to trans-radial approach in high volume cardiac center and to identify factors associated with the development of RAS. Methods It is a prospective, randomized, double blind and placebo-controlled trial conducted in a single high volume cardiac center in Saudi Arabia from July to November 2017. Patients who met the inclusion criteria were randomized to either a cocktail vasodilators (nitroglycerin and verapamil) or matching placebo (normal saline) in 1:1 ratio. Subjective definition of RAS was utilized, consistent with previous studies. The primary outcome is the development of RAS in both groups. The secondary outcome is identifying the factors associated with the development of RAS. The calculated sample size is 315 patients. Data analysis was performed using SPSS 20 and STATA 15 softwares. Multiple stepwise logistic regression was used to examine the association between the study variables and incidence of RAS. Results A total of 490 patients were randomized (244 in placebo and 246 in treatment groups). There were no differences in the baseline demographic and clinical characteristics between both groups. Significantly, higher proportion of patients on the placebo group had RAS compared to those on the treatment group (23% vs 11%; p = 0.001). After controlling for the other factors, patients on the treatment were less likely to develop RAS than those on the placebo (OR= 0.32; p <0.001). The independent risk factors associated with the occurrence of RAS are: female gender (OR= 6.18; p <0.001), multiple puncture attempts (OR= 2.83; p = 0.003), current smoking (OR= 3.02; p =0.03) and using dihydropyridine calcium channel blockers (OR= 4.60; p <0.001). We did not find a significant relationship between operators’ level of experience and the occurrence of RAS. Conclusion The use of cocktail vasodilators reduces the incidence of RAS regardless to the hospital volume and operators experience. Further studies on factors associated with RAS is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.